Therapeutics News and Research

RSS
Insulin metabolism regulates body's internal clock

Insulin metabolism regulates body's internal clock

Nimotuzumab drug approved for Mexican distribution

Nimotuzumab drug approved for Mexican distribution

Intarcia's ITCA 650 phase 2 study in type 2 diabetes begins patient enrollment

Intarcia's ITCA 650 phase 2 study in type 2 diabetes begins patient enrollment

CI Index of ten leading cancer immunotherapy stocks increase by 58% in two months

CI Index of ten leading cancer immunotherapy stocks increase by 58% in two months

Pervasis Therapeutics raises funds to support clinical development programs

Pervasis Therapeutics raises funds to support clinical development programs

Amgen granted approval to use ImmunoGen’s maytansinoid TAP technology

Amgen granted approval to use ImmunoGen’s maytansinoid TAP technology

Nuveta closes Series A seed financing round for in vitro fertilization research

Nuveta closes Series A seed financing round for in vitro fertilization research

FDA approves Sirion's Zirgan for treating acute herpetic keratitis

FDA approves Sirion's Zirgan for treating acute herpetic keratitis

The first successful implantation of the GDS Accucinch System for mitral valve repair

The first successful implantation of the GDS Accucinch System for mitral valve repair

CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval

CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval

Santaris Pharma establishes its operations in the U.S.

Santaris Pharma establishes its operations in the U.S.

Next Generation Advanced Image Processing for Toshiba Infinix-i product line

Next Generation Advanced Image Processing for Toshiba Infinix-i product line

New therapies boost obesity drug market

New therapies boost obesity drug market

RXi Pharmaceuticals to present in vivo data of rxRNA compounds

RXi Pharmaceuticals to present in vivo data of rxRNA compounds

Toll-like receptors that activate immune cells being developed as alternative cure to cancer

Toll-like receptors that activate immune cells being developed as alternative cure to cancer

EVEREST clinical trial results to be presented at the upcoming TCT Conference

EVEREST clinical trial results to be presented at the upcoming TCT Conference

LEAD Therapeutics' LT-29 antibiotic effective against most common antibiotic resistant bacteria

LEAD Therapeutics' LT-29 antibiotic effective against most common antibiotic resistant bacteria

GENova allies with academic institutions specializing in stem cell research

GENova allies with academic institutions specializing in stem cell research

Phase III EXTEND trial results of pixantrone announced

Phase III EXTEND trial results of pixantrone announced

BCLI collaborates with HBI to complete pre-clinical safety experiments

BCLI collaborates with HBI to complete pre-clinical safety experiments